Note: before purchasing and taking medicines, a hospital genetic test report and a doctor's diagnosis report or certificate must be produced
1. Unresectable, locally advanced or metastatic symptomatic or progressing medullary thyroid cancer
2. Together with everolimus, it can be used to treat renal cell carcinoma (RCC, a cancer that begins in the kidney) in people who have previously been treated with another chemotherapeutic agent.
3. For hepatocellular carcinoma (HCC; a form of liver cancer) that cannot be treated with surgery
4. Radioiodine refractory differentiated thyroid cancer patients with local recurrence / metastasis, progression
5. Together with pembrolizumab, the PD-1 inhibitor pabolizumab, it is used to treat a type of endometrial cancer (endometrial cancer) that has spread to other parts of the body or has worsened during or after treatment with chemotherapeutic agents or cannot be treated with surgery or radiotherapy.
1. Thyroid cancer (DTC): 24mg daily, orally, once daily;
2. Renal cell carcinoma (RCC): 18 mg lenvatinib + 5 mg everolimus, oral, once daily;
3. Hepatocellular carcinoma (HCC): body weight ≥ 60 kg, 12 mg, once daily; Body weight < 60 kg, 8 mg once daily.
Lenvatinib was required to be taken at the same time daily. If the medication is forgotten and fails to take it orally within 12 hours, this dose should be skipped and the next dose taken at the time of the original dose.
The lenvatinib capsule should be swallowed as a whole, or taken after dissolving the capsule in a small glass of liquid. A large tablespoon of water or apple juice can be taken and placed into a capsule after it is placed in a glass (the capsule does not need to be opened or crushed). After resting the capsules in liquid for at least 10 min and stirring for at least 3 min, the liquid was drunk. After drinking, add an equal volume (one large tablespoon) of water or apple juice to the glass and mix well before drinking the remaining liquid.
This product is contraindicated in patients who have known hypersensitivity to lenvatinib or any of the excipients.
In DTC, common adverse effects (incidence greater than or equal to 30%) for lenvima are hypertension, fatigue, diarrhea, arthralgia myalgia, decreased appetite, weight loss, nausea, stomatitis, headache, vomiting, proteinuria, palmoplantar erythrodysesthesia syndrome, abdominal pain, dysphonia.
In renal cancer, common adverse reactions (greater than 30%) for lenvima + everolimus were diarrhea, fatigue, arthralgia myalgia, loss of appetite, vomiting, nausea, stomatitis oral inflammation, hypertension, peripheral edema, cough, abdominal pain, dyspnea decreased, rash, significant weight loss, bleeding events, proteinuria.